Cagrilintide
Also known as: AM833 · Long-acting amylin analog
A long-acting amylin analog being co-developed with semaglutide (as CagriSema) for obesity. Amylin signals satiety to the brain independently of GLP-1, making the combination synergistic for weight loss.
What is Cagrilintide? A long-acting amylin analog being co-developed with semaglutide (as CagriSema) for obesity. Amylin signals satiety to the brain independently of GLP-1, making the combination synergistic for weight loss.
How does Cagrilintide work? Cagrilintide activates amylin (calcitonin family) receptors in the brainstem and hypothalamus, signaling satiety and reducing food intake. When combined with semaglutide (CagriSema), the dual satiety mechanism produced 25.1% weight loss in Phase 3 trials — approaching the results of bariatric surgery.
Benefits of Cagrilintide: Signals satiety via amylin pathway — distinct from GLP-1; Combined with semaglutide: 25.1% weight loss (Phase 3); Reduces food intake and increases feeling of fullness; Slows gastric emptying complementary to GLP-1; Potential for superior weight loss vs. tirzepatide
Cagrilintide dosage: Phase 3 trials use cagrilintide 2.4mg + semaglutide 2.4mg (CagriSema). Stand-alone dose being established.
Cagrilintide half-life: ~7 days
Research status: Clinical Trials
Source: PeptideWiki — https://www.peptide-wiki.net/peptides/cagrilintide
Mechanism of Action
Cagrilintide activates amylin (calcitonin family) receptors in the brainstem and hypothalamus, signaling satiety and reducing food intake. When combined with semaglutide (CagriSema), the dual satiety mechanism produced 25.1% weight loss in Phase 3 trials — approaching the results of bariatric surgery.
Amino Acid Sequence (37 AAs)
Modified 37-AA amylin backbone with fatty acid chain
Benefits
- Signals satiety via amylin pathway — distinct from GLP-1
- Combined with semaglutide: 25.1% weight loss (Phase 3)
- Reduces food intake and increases feeling of fullness
- Slows gastric emptying complementary to GLP-1
- Potential for superior weight loss vs. tirzepatide
Side Effects & Risks
- Nausea (especially when combined with semaglutide)
- Vomiting
- Constipation
- Injection site reactions
- Currently only in clinical trials
Where to Buy Cagrilintide
2 options across 1 vendor · Sorted cheapest first · All include direct product link
From
$99.99
All links are affiliate links — PeptideWiki earns a commission at no extra cost to you. Coupon codes apply at checkout. Prices and availability may change. Always verify COA before purchasing.
Storage & Reconstitution Guide
Storage Temperature
-20°C lyophilized, 4°C reconstituted
24 months (lyophilized), 28 days (reconstituted)
Reconstitution Solvent
Bacteriostatic water (BAC water)
Swirl gently — do not shake or vortex
Handling Notes
Protect lyophilized peptide from moisture and light. Once reconstituted, keep refrigerated. Discard if solution becomes cloudy or discolored. Use insulin syringe for precise dosing.
Step-by-Step Reconstitution
Gather supplies
BAC water, insulin syringe, alcohol swabs, vial
Disinfect tops
Swab rubber stoppers of both vials with alcohol
Draw BAC water
Pull desired mL of BAC water into syringe
Inject slowly
Inject BAC water down the side of the peptide vial, swirl gently to dissolve
Clinical Trials & Human Studies2 trials
Cagrilintide combined with semaglutide for obesity treatment (CagriSema)
CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) produced 25.1% weight reduction in Phase 3 REDEFINE 1 trial.
Phase 2: Cagrilintide for Obesity Weight Loss
Dose-escalation RCT in 706 adults with overweight/obesity. Cagrilintide 4.5mg/week: -10.8% weight loss vs -3.0% placebo at 26 weeks (treatment difference -7.8%, 95% CI -9.2 to -6.4; p<0.001). Superior to liraglutide 3mg: -10.8% vs -9.0% (p=0.03).
Primary Outcome
Weight change from baseline at 26 weeks
95% CI
-9.2 to -6.4
p-value
<0.001
Placebo
-3.0%
Vs Liraglutide
-10.8% vs -9.0% (p=0.03)
Cagrilintide 4.5mg
-10.8%
Treatment Difference
-7.8%
Research Protocol
- Dose Range
- 0.3–2.4 mg
- Frequency
- Once weekly subcutaneous injection
- Cycle
- Ongoing / chronic
- Half-Life
- ~7 days
- Routes
- subcutaneous injection
- Notes
- Phase 3 trials use cagrilintide 2.4mg + semaglutide 2.4mg (CagriSema). Stand-alone dose being established.
Legal & Regulatory Status
Sold for research purposes only. Not for human use. Laws vary by country.
Commonly Stacked With
View all peptide stacks →External Resources
PeptideWiki Research Team
Evidence-based research data sourced from PubMed and ClinicalTrials.gov · Last updated: February 25, 2026
Frequently Asked Questions About Cagrilintide
What is Cagrilintide?▾
A long-acting amylin analog being co-developed with semaglutide (as CagriSema) for obesity. Amylin signals satiety to the brain independently of GLP-1, making the combination synergistic for weight loss.
What are the benefits of Cagrilintide?▾
Signals satiety via amylin pathway — distinct from GLP-1
What are the benefits of Cagrilintide?▾
Combined with semaglutide: 25.1% weight loss (Phase 3)
What are the side effects of Cagrilintide?▾
Nausea (especially when combined with semaglutide)
What is the recommended dosage for Cagrilintide?▾
Phase 3 trials use cagrilintide 2.4mg + semaglutide 2.4mg (CagriSema). Stand-alone dose being established.
How long should a Cagrilintide cycle last?▾
Ongoing / chronic
More Weight Management Peptides
View all Weight Management peptides →5-Amino-1MQ
5-Amino-1-methylquinolinium
A small molecule inhibitor of NNMT enzyme that boosts metabolism and promotes fat cell apoptosis. Shows promise as a novel anti-obesity agent in preclinical research.
Retatrutide
LY3437943
An emerging triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials show unprecedented weight loss of up to 24% body weight.
AOD-9604
AOD9604
A synthetic fragment of the C-terminus of HGH (amino acids 176-191) that retains the fat-burning properties of growth hormone without affecting blood sugar or IGF-1 levels.
MOTS-C
Mitochondrial Open Reading Frame of the 12S rRNA-c
A mitochondria-derived peptide that acts as a metabolic regulator, improving insulin sensitivity, exercise capacity, and potentially mimicking caloric restriction.